BEIJING – Shenzhen-listed Chinese firm Nanjing Hicin Pharmaceutical Co. Ltd. has in-licensed an isocitrate dehydrogenase (IDH) inhibitor known as I111b from Italian oncology specialist Nerviano Medical Sciences Srl (NMS) to develop and commercialize the drug globally for patients with acute myeloid leukemia (AML). Read More
LONDON – The largest-ever genomics study of Clostridium difficile has found an emerging new species of the bacterium is selected to thrive on a Western sugar-rich diet and to produce high levels of resistant spores, adapting it to maximize transmission in hospitals and other health care facilities. Read More
BOGOTA, Colombia - Grupo Laboratorios Imperiales Pharma SA de C.V. (Laboratorios Imperiales), from Jiutepec, Mexico, the distributor of measles-rubella (MR) and measles, mumps and rubella (MMR) vaccines manufactured by Serum Institute of India Pvt. Ltd., was banned from signing public contracts with Mexico's public entities for 27 months and fined MX$1.088 million (US$55,478) after it breached two public contracts with the country's Secretariat of Health to provide the country with vaccines. Read More
PERTH, Australia – San Diego-based Okogen Inc. is taking its clinical trial program to Australia where it will test its lead compound OKG-0301 for acute adenoviral conjunctivitis in the phase II (RUBY) trial. Read More
Telix Pharmaceuticals Ltd., of Melbourne, Australia, and Genesiscare Pty Ltd., a provider of cancer and cardiac services, were cleared to start the Enhancing study, a phase II imaging study comparing the expression of prostate-specific membrane antigen, before and after treatment with Xtandi (enzalutamide, Astellas Pharma Inc.), using PET. Read More
Astellas Pharma Inc., of Tokyo, appointed David Fryrear senior vice president and head of clinical and research quality assurance (CRQA) in its Medical and Development (M&D) organization. Read More
We're working to enhance BioWorld's news services by moving to a brand-new platform later this year. Upgrades will include: same-day news delivery, improved functionality, easier accessibility on all devices, more analysis and dynamic data visualization. We value your opinion on these changes. Please take 2 minutes to complete this short survey to help guide our work: https://www.surveymonkey.com/r/Q5TK8JL Read More
HONG KONG – Aiming to accelerate its biopharmaceutical R&D and marketing approvals, South Korea's Ministry of Food and Drug Safety (MFDS) and Ministry of Health and Welfare recently announced the Proposal of Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety and Support Act had passed the country's National Assembly plenary session at the beginning of August and will come into force in a year's time. Read More
